Benitec Biopharma Ltd (BNTC)

[RCH68]

A guy was saying that a month or so ago jokingly. Or at least I thought he was joking. I think it might have been Buda but can't remember.
Here is what Panno said about it a few days ago.


I think that the company has inadvertently created a rod for its own back when it comes to reporting to the market on TT-034. Having promised to report on both the first and second dosing in each cohort, the company now finds itself damned if it reports more delays, damned if it does not report at all and viewed apathetically if it reports what the market expects.

I think that we will get some announcement this week or early next week and I would hope that the announcement contains more than just an update in the dosing of the second patient. I hope it says that the company has been in discussions with the FDA and that the FDA is considering allowing the inclusions of any genotype 1 patients, not just those who are considered non-responders.

This would be good news and, if the inclusion criteria were to change, then we could see the trial get back on track.